InsiderTrades.com logo
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Jeffrey Tate net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeffrey Tate Biography and Net Worth

COO of Cyclo Therapeutics
Dr. Tate is a seasoned executive with more than 30 years of operations experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, experienced in implementation of all aspects of regulatory compliance and in successfully communicating with regulatory agency representatives.

Dr. Tate has successfully established compliant regulated manufacturing operations and integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.

What is Jeffrey Tate's net worth?

The estimated net worth of Jeffrey Tate is at least $45,333.73 as of April 20th, 2023. Dr. Tate owns 62,101 shares of Cyclo Therapeutics stock worth more than $45,334 as of November 23rd. This net worth estimate does not reflect any other investments that Dr. Tate may own. Additionally, Dr. Tate receives an annual salary of $255,140.00 as COO at Cyclo Therapeutics. Learn More about Jeffrey Tate's net worth.

How old is Jeffrey Tate?

Dr. Tate is currently 66 years old. There are 4 older executives and no younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics is Mr. C. E Strattan, Founder & Director, who is 78 years old. Learn More on Jeffrey Tate's age.

What is Jeffrey Tate's salary?

As the COO of Cyclo Therapeutics, Inc., Dr. Tate earns $255,140.00 per year. There are 3 executives that earn more than Dr. Tate. The highest earning executive at Cyclo Therapeutics is Mr. N. Scott Fine, CEO & Director, who commands a salary of $569,920.00 per year. Learn More on Jeffrey Tate's salary.

How do I contact Jeffrey Tate?

The corporate mailing address for Dr. Tate and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]. Learn More on Jeffrey Tate's contact information.

Has Jeffrey Tate been buying or selling shares of Cyclo Therapeutics?

Jeffrey Tate has not been actively trading shares of Cyclo Therapeutics in the last ninety days. Most recently, on Thursday, April 20th, Jeffrey Tate bought 29,941 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $0.71 per share, with a total value of $21,258.11. Following the completion of the transaction, the chief operating officer now directly owns 62,101 shares of the company's stock, valued at $44,091.71. Learn More on Jeffrey Tate's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Jeffrey Tate Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2023Buy29,941$0.71$21,258.1162,101View SEC Filing Icon  
5/16/2022Buy3,000$2.12$6,360.0032,160View SEC Filing Icon  
4/28/2022Buy635$2.50$1,587.5027,795View SEC Filing Icon  
3/29/2021Buy2,000$7.50$15,000.0027,160View SEC Filing Icon  
See Full Table

Jeffrey Tate Buying and Selling Activity at Cyclo Therapeutics

This chart shows Jeffrey Tate's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More

Today's Range

Now: $0.73
Low: $0.68
High: $0.77

50 Day Range

MA: $0.73
Low: $0.61
High: $0.81

2 Week Range

Now: $0.73
Low: $0.59
High: $2.12

Volume

17,336 shs

Average Volume

67,859 shs

Market Capitalization

$21.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.